| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Division of Molecular Regenerative Medicine, Course of Advanced Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871 [D. T., K. K., K. Ma., T. N.] and Department of Surgery and Oncology, Kyushu University Graduate School of Medical Science, Maidashi, Fukuoka 812-8582 [N. M., K. Mi., M. T.], Japan
Hepatocyte growth factor (HGF) is involved in malignant behavior of cancers as a mediator in tumor-stromal interactions through enhancing tumor invasion and metastasis. We found recently that NK4, a four-kringle fragment of HGF, functions as both an HGF-antagonist and an angiogenesis inhibitor. We have now determined whether blockade of the HGF-c-Met/HGF receptor pathway and tumor angiogenesis by administration of recombinant NK4 would inhibit growth, invasion, and metastasis of human pancreatic carcinoma implanted into the pancreas of nude mice. When treatment with NK4 or anti-HGF neutralizing antibody was initiated from the third day after orthotopic injection of SUIT-2 human pancreatic cancer cells, both NK4 and anti-HGF antibody suppressed the conversion of orthotopic pancreatic tumors from carcinoma in situ to aberrantly invading cancers during days 3–14. On the other hand, when the treatment was begun on day 10, a time when cancer cells were already invading surrounding tissues, NK4 but not anti-HGF antibody inhibited tumor growth, peritoneal dissemination, and ascites accumulation at 4 weeks after the inoculation. Antitumor effects of NK4 correlated with decreased microvessel density in pancreatic tumors thereby indicating that the antiangiogenic activity of NK4 may have mainly contributed to its antitumor effects. Moreover, although NK4-treatment was initiated from the end stage (day 24 after tumor inoculation), NK4 prolonged survival time of mice, and the suppression of peritoneal dissemination, ascites accumulation, and invasion of metastasized cancer cells into the peritoneal wall were remarkable. We propose that simultaneous targeting of both tumor angiogenesis and the HGF-mediated invasion-metastasis may prove to be a new approach to treating patients with pancreatic cancer.
This article has been cited by other articles:
|
|
 |
|
  M. J. Binning, T. Niazi, C. A. Pedone, B. Lal, C. G. Eberhart, K. J. Kim, J. Laterra, and D. W. Fults Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth Cancer Res., October 1, 2008; 68(19): 7838 - 7845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jin, R. Yang, Z. Zheng, M. Romero, J. Ross, H. Bou-Reslan, R. A.D. Carano, I. Kasman, E. Mai, J. Young, et al. MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival Cancer Res., June 1, 2008; 68(11): 4360 - 4368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Bellon, P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C. W. Johnson, P. E. Rose, A. M. Long, A. B. O'Connor, et al. c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations J. Biol. Chem., February 1, 2008; 283(5): 2675 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Jia, J. Zhang, D. Wei, L. Wang, P. Yuan, X. Le, Q. Li, J. Yao, and K. Xie Molecular Basis of the Synergistic Antiangiogenic Activity of Bevacizumab and Mithramycin A Cancer Res., May 15, 2007; 67(10): 4878 - 4885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Du, Y. Hattori, T. Yamada, K. Matsumoto, T. Nakamura, M. Sagawa, T. Otsuki, T. Niikura, T. Nukiwa, and Y. Ikeda NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor Blood, April 1, 2007; 109(7): 3042 - 3049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tsutsumi, T. Yanagawa, T. Shimura, H. Kuwano, and A. Raz Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis Clin. Cancer Res., November 15, 2004; 10(22): 7775 - 7784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sato, N. Maehara, and M. Goggins Gene Expression Profiling of Tumor-Stromal Interactions between Pancreatic Cancer Cells and Stromal Fibroblasts Cancer Res., October 1, 2004; 64(19): 6950 - 6956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ohuchida, K. Mizumoto, M. Murakami, L.-W. Qian, N. Sato, E. Nagai, K. Matsumoto, T. Nakamura, and M. Tanaka Radiation to Stromal Fibroblasts Increases Invasiveness of Pancreatic Cancer Cells through Tumor-Stromal Interactions Cancer Res., May 1, 2004; 64(9): 3215 - 3222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Iacobuzio-Donahue, R. Ashfaq, A. Maitra, N. V. Adsay, G. L. Shen-Ong, K. Berg, M. A. Hollingsworth, J. L. Cameron, C. J. Yeo, S. E. Kern, et al. Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies Cancer Res., December 15, 2003; 63(24): 8614 - 8622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shinomiya and G. F. Vande Woude Suppression of Met Expression: A Possible Cancer Treatment: Commentary re: S. J. Kim et al., Reduced c-Met Expression by an Adenovirus Expressing a c-Met Ribozyme Inhibits Tumorigenic Growth and Lymph Node Metastases of PC3-LN4 Prostate Tumor Cells in an Orthotopic Nude Mouse Model. Clin. Cancer Res., 14: 5161-5170, 2003. Clin. Cancer Res., November 1, 2003; 9(14): 5085 - 5090. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, P. Le, C. Liang, J. Chan, D. Kiewlich, T. Miller, D. Harris, L. Sun, A. Rice, S. Vasile, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion Mol. Cancer Ther., November 1, 2003; 2(11): 1085 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Brockmann, A. Papadimitriou, M. Brandt, R. Fillbrandt, M. Westphal, and K. Lamszus Inhibition of Intracerebral Glioblastoma Growth by Local Treatment with the Scatter Factor/Hepatocyte Growth Factor-Antagonist NK4 Clin. Cancer Res., October 1, 2003; 9(12): 4578 - 4585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sattler, Y. B. Pride, P. Ma, J. L. Gramlich, S. C. Chu, L. A. Quinnan, S. Shirazian, C. Liang, K. Podar, J. G. Christensen, et al. A Novel Small Molecule Met Inhibitor Induces Apoptosis in Cells Transformed by the Oncogenic TPR-MET Tyrosine Kinase Cancer Res., September 1, 2003; 63(17): 5462 - 5469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. PAI, T. NAKAMURA, W. S. MOON, and A. S. TARNAWSKI Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors FASEB J, September 1, 2003; 17(12): 1640 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Manabe, K. Mizumoto, E. Nagai, K. Matsumoto, T. Nakamura, T. Nukiwa, M. Tanaka, and T. Matsuda Cell-based Protein Delivery System for the Inhibition of the Growth of Pancreatic Cancer: NK4 Gene-transduced Oral Mucosal Epithelial Cell Sheet Clin. Cancer Res., August 1, 2003; 9(8): 3158 - 3166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Martin, C. Parr, G. Davies, G. Watkins, J. Lane, K. Matsumoto, T. Nakamura, R. E. Mansel, and W. G. Jiang Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist Carcinogenesis, August 1, 2003; 24(8): 1317 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chattopadhyay, R. J. MacLeod, J. Tfelt-Hansen, and E. M. Brown 1alpha ,25(OH)2-vitamin D3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E219 - E227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kikuchi, M. Maemondo, K. Narumi, K. Matsumoto, T. Nakamura, and T. Nukiwa Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells Blood, December 1, 2002; 100(12): 3950 - 3959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-G. Tong, X.-Z. Ding, R. Hennig, R. C. Witt, J. Standop, P. M. Pour, and T. E. Adrian Leukotriene B4 Receptor Antagonist LY293111 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells Clin. Cancer Res., October 1, 2002; 8(10): 3232 - 3242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saimura, E. Nagai, K. Mizumoto, N. Maehara, Y. A. Minamishima, M. Katano, K. Matsumoto, T. Nakamura, and M. Tanaka Tumor Suppression through Angiogenesis Inhibition by SUIT-2 Pancreatic Cancer Cells Genetically Engineered to Secrete NK4 Clin. Cancer Res., October 1, 2002; 8(10): 3243 - 3249. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
